

# NEXT-GENERATION SEQUENCING: EMERGING CLINICAL APPLICATIONS AND GLOBAL MARKETS



**BIO126B**  
**June 2015**

John Bergin  
***Project Analyst***

ISBN: 1-62296-111-0



**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481 USA**  
**866-285-7215 (toll-free within the USA),**  
**or (+1) 781-489-7301**  
**[www.bccresearch.com](http://www.bccresearch.com)**  
**[information@bccresearch.com](mailto:information@bccresearch.com)**

**TABLE OF CONTENTS**

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE	3
SCOPE AND FORMAT	3
METHODOLOGY	4
INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL CLINICAL NEXT-GENERATION SEQUENCING MARKET BY DISEASE CLASS, THROUGH 2020 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL CLINICAL NEXT-GENERATION SEQUENCING MARKET BY DISEASE CLASS, 2014-2020 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	11
INTRODUCTION	11
<i>TABLE 1 REPORT SCOPE</i>	11
CLINICAL NGS MARKETS	11
<i>TABLE 2 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY DISEASE TYPE, THROUGH 2020 (\$ MILLIONS)</i>	12
CLINICAL NGS GROWTH DRIVING FORCES	13
TECHNOLOGY DRIVERS	13
<i>TABLE 3 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT-GENERATION SEQUENCING</i>	13
MARKET DRIVERS	14
<i>TABLE 4 CLINICAL NEXT-GENERATION SEQUENCING MARKET DRIVING FORCES</i>	15
CLINICAL NGS APPLICATIONS	16
<i>TABLE 5 CLINICAL NEXT-GENERATION SEQUENCING APPLICATION STATUS</i>	16
CLINICAL NGS INDUSTRY	17
<i>TABLE 6 KEY DIAGNOSTIC NEXT-GENERATION SEQUENCING INDUSTRY PARTICIPANTS BY SECTOR</i>	17
CHAPTER 4 TECHNOLOGIES	20
IMPORTANCE OF DNA	20
<i>TABLE 7 DNA CHEMICAL BUILDING BLOCKS</i>	20
<i>TABLE 8 DNA TRANSLATION AND TRANSCRIPTION</i>	20
<i>TABLE 9 LONG-RANGE DNA STRUCTURE</i>	21
GENETIC VARIATION AND ANALYSIS	22
<i>TABLE 10 GENETIC VARIANT TYPES</i>	22
GENETIC ANALYSIS TECHNOLOGIES	23
<i>TABLE 11 IMPORTANT MOLECULAR DIAGNOSTIC PLATFORMS</i>	24
NGS IN CLINICAL APPLICATIONS	25

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 12 GENETIC TESTING EVOLUTION</i>	25
<i>TABLE 13 MARKET SEGMENTS FOR NEXT-GENERATION SEQUENCING DIAGNOSTICS</i>	26
NGS TECHNOLOGIES	27
HISTORY OF DNA SEQUENCING	27
<i>TABLE 14 DNA SEQUENCING HISTORICAL TIMELINE, 1977-2015</i>	28
<i>TABLE 15 SEQUENCING TECHNOLOGY DEVELOPMENT, 1990-2020</i>	33
<i>FIGURE 1 EFFECT OF NEW SEQUENCING TECHNOLOGIES ON COST TO SEQUENCE A SINGLE HUMAN GENOME, 2001-2014 [3] (\$/GENOME)</i>	34
SANGER SEQUENCING TECHNOLOGY	35
<i>TABLE 16 SANGER SEQUENCING SUMMARY</i>	35
<i>TABLE 17 SANGER SEQUENCING IMPROVEMENTS</i>	36
NGS PLATFORMS	36
<i>TABLE 18 NEXT-GENERATION SEQUENCING TECHNOLOGIES</i>	37
<i>TABLE 19 ROCHE NEXT-GENERATION SEQUENCING WORKFLOW</i>	37
<i>TABLE 20 ILLUMINA NEXT-GENERATION SEQUENCING WORKFLOW</i>	38
<i>TABLE 21 LIFE TECHNOLOGIES NEXT-GENERATION SEQUENCING WORKFLOW</i>	39
BENCHTOP SEQUENCERS	40
<i>TABLE 22 BENCHTOP SEQUENCER PLATFORMS</i>	40
NANOPORE SEQUENCING TECHNOLOGIES	41
INFORMATICS TECHNOLOGIES	42
<i>TABLE 23 NEXT-GENERATION SEQUENCING BIOINFORMATICS WORKFLOW</i>	42
BASE CALLING	43
MAPPING TO A REFERENCE SEQUENCE	43
<i>TABLE 24 SEQUENCE ANNOTATION STEPS</i>	44
VARIANT ANALYSIS	45
FUTURE TECHNOLOGY CHALLENGES	46
<i>TABLE 25 FUTURE CHALLENGES FOR IMPLEMENTING CLINICAL NEXT-GENERATION SEQUENCING</i>	46
CHAPTER 5 TOP 10 CLINICAL NGS INITIATIVES	49
<i>TABLE 26 TOP 10 CLINICAL NEXT-GENERATION SEQUENCING PROJECTS</i>	49
ACTIONABLE GENOME CONSORTIUM	50
BABYSEQ	50
CANCER MOON SHOTS PROGRAM	50
CLINGEN	50
LUNG-MAP	51
MATCHMAKER EXCHANGE	51
MILLION VETERAN PROGRAM	51
MEDSEQ	52
PRECISION MEDICINE	52
PROMPT	52
CHAPTER 6 CLINICAL NGS APPLICATIONS	54
INTRODUCTION	54
<i>TABLE 27 CLINICAL NEXT-GENERATION SEQUENCING, NEAR TO MID-TERM APPLICATIONS</i>	54
CANCER APPLICATIONS	55
<i>TABLE 28 CANCER APPLICATIONS</i>	55

<b>TOPIC</b>	<b>PAGE NO.</b>
MENDELIAN DISORDERS APPLICATIONS	57
<i>TABLE 29 MENDELIAN DISORDERS APPLICATIONS</i>	57
REPRODUCTIVE HEALTH APPLICATIONS	58
<i>TABLE 30 SCREENING APPLICATIONS</i>	58
<i>TABLE 31 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN SCREENING</i>	60
INFECTIOUS DISEASE APPLICATIONS	61
<i>TABLE 32 INFECTIOUS DISEASE APPLICATIONS</i>	62
COMPLEX DISORDERS APPLICATIONS	63
<i>TABLE 33 COMPLEX DISORDER APPLICATIONS</i>	64
CHAPTER 7 CLINICAL NGS INDUSTRY	67
INTRODUCTION	67
<i>TABLE 34 KEY SEGMENTS WITHIN THE NEXT-GENERATION SEQUENCING CLINICAL INDUSTRY</i>	67
NGS INSTRUMENT INDUSTRY	68
<i>TABLE 35 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES SUMMARY</i>	68
NGS TARGET ENRICHMENT INDUSTRY	71
<i>TABLE 36 NEXT-GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY</i>	71
NGS CLINICAL INFORMATICS INDUSTRY	72
<i>TABLE 37 NEXT-GENERATION SEQUENCING CLINICAL INFORMATICS COMPANY POSITIONING</i>	73
NGS CLINICAL LABORATORY TESTING SERVICES INDUSTRY	75
<i>TABLE 38 NGS CLINICAL LABORATORY TESTING SERVICES INDUSTRY</i>	75
INDIA'S CLINICAL SEQUENCING INDUSTRY	78
<i>TABLE 39 INDIA NGS CLINICAL SEQUENCING COMPETITIVE POSITIONING</i>	78
REPRODUCTIVE HEALTH DIAGNOSTICS INDUSTRY	79
NONINVASIVE PRENATAL TESTING INDUSTRY	79
<i>TABLE 40 NGS NIPT INDUSTRY</i>	80
<i>TABLE 41 GLOBAL NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC MARKET SHARE BY TEST, 2014 (%)</i>	84
<i>TABLE 42 GERMANY NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC COMPETITIVE SITUATION</i>	85
PREIMPLANTATION GENETICS DIAGNOSIS/SCREENING INDUSTRY	87
<i>TABLE 43 PREIMPLANTATION DIAGNOSTICS PLATFORMS</i>	87
<i>TABLE 44 PREIMPLANTATION GENETIC SCREENING AND DIAGNOSIS INDUSTRY</i>	88
LIQUID BIOPSY INDUSTRY	91
<i>TABLE 45 NGS-BASED LIQUID BIOPSY INDUSTRY</i>	92
HLA TYPING INDUSTRY	94
<i>TABLE 46 NGS-BASED HLA TYPING INDUSTRY COMPETITORS</i>	95
IMMUNE SEQUENCING INDUSTRY	97
<i>TABLE 47 IMMUNE SYSTEM PROFILING INDUSTRY</i>	97
NGS GENE FUSION DIAGNOSTICS INDUSTRY	98
<i>TABLE 48 NGS-BASED GENE FUSION DIAGNOSTICS INDUSTRY</i>	99
CLINICAL NGS INDUSTRY ACQUISITIONS AND STRATEGIC ALLIANCES	100
ACQUISITIONS	100
<i>TABLE 49 CLINICAL NEXT-GENERATION SEQUENCING INDUSTRY ACQUISITIONS, 2013- MARCH 2015</i>	100

<b>TOPIC</b>	<b>PAGE NO.</b>
STRATEGIC ALLIANCES	104
<i>TABLE 50 CLINICAL NEXT-GENERATION SEQUENCING STRATEGIC ALLIANCES, 2013-MARCH 2015</i>	105
CHAPTER 8 NGS DIAGNOSTICS MARKETS	119
GROWTH DRIVING FORCES	119
<i>TABLE 51 CLINICAL NEXT-GENERATION SEQUENCING KEY GROWTH DRIVING FORCES, THROUGH 2020</i>	119
<i>TABLE 52 CLINICAL NGS STAKEHOLDERS ACTIVITY</i>	121
GLOBAL NGS DIAGNOSTIC MARKET	122
<i>TABLE 53 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)</i>	123
<i>TABLE 54 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	124
NGS CANCER DIAGNOSTIC MARKETS	126
<i>TABLE 55 GLOBAL NEXT-GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY SEGMENT, THROUGH 2020 (\$ MILLIONS)</i>	126
<i>TABLE 56 GLOBAL NEXT-GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	129
NGS Cancer Diagnosis Market	130
NGS Cancer Screening Market	130
NGS Cancer Monitoring Market	130
NGS Cancer Therapy Guidance Market	131
Companion Diagnostics	132
<i>TABLE 57 RECENT NGS-BASED COMPANION DIAGNOSTICS ACTIVITIES</i>	132
Thyroid and Leukemia Update	134
NGS Cancer Market by Test Complexity	134
<i>TABLE 58 GLOBAL CANCER NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)</i>	135
<i>TABLE 59 MULTI-GENE NGS-BASED HEMATOLOGICAL TESTS</i>	137
NGS CARDIOLOGY DIAGNOSTIC MARKETS	137
<i>TABLE 60 GLOBAL NEXT-GENERATION SEQUENCING CARDIOVASCULAR DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	138
<i>TABLE 61 DILATED CARDIOMYOPATHY TEST PROVIDERS</i>	139
<i>TABLE 62 GLOBAL NEXT-GENERATION SEQUENCING CARDIOLOGY DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)</i>	140
NGS MENDELIAN DISORDERS DIAGNOSTIC MARKETS	140
<i>TABLE 63 GLOBAL NEXT-GENERATION SEQUENCING MENDELIAN DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	142
<i>TABLE 64 GLOBAL NEXT-GENERATION SEQUENCING MENDELIAN DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)</i>	143
NGS METABOLIC/IMMUNE DISORDER DIAGNOSTIC MARKETS	145
<i>TABLE 65 GLOBAL NEXT-GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	146
<i>TABLE 66 MULTIPLE SCLEROSIS DIAGNOSTIC TECHNOLOGIES</i>	146
<i>TABLE 67 GLOBAL NEXT-GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)</i>	147
NGS NEUROLOGY DIAGNOSTIC MARKETS	148

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 68 GLOBAL NEXT-GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	148
<i>TABLE 69 GLOBAL NEXT-GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)</i>	149
NGS REPRODUCTIVE HEALTH DIAGNOSTIC MARKETS	150
Newborn Screening Diagnostic Market	150
<i>TABLE 70 GLOBAL NEXT-GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	151
<i>TABLE 71 GLOBAL NEXT-GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)</i>	152
Prenatal Screening Diagnostic Market	153
<i>TABLE 72 GLOBAL NEXT-GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	154
<i>TABLE 73 GLOBAL NEXT-GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)</i>	156
Preimplantation Diagnostic Market	157
<i>TABLE 74 GLOBAL NEXT-GENERATION SEQUENCING PREIMPLANTATION DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	157
<i>TABLE 75 GLOBAL NEXT-GENERATION SEQUENCING PREIMPLANTATION DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)</i>	158
NGS FOOD-BORNE ILLNESS DIAGNOSTIC MARKET	159
<i>TABLE 76 GLOBAL NEXT-GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	160
<i>TABLE 77 GLOBAL NEXT-GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)</i>	160
<i>TABLE 78 NGS IN INFECTIOUS DISEASE DIAGNOSTICS</i>	161
NGS HLA TYPING DIAGNOSTIC MARKET	161
<i>TABLE 79 GLOBAL NEXT-GENERATION SEQUENCING HLA TYPING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	162
<i>TABLE 80 GLOBAL NEXT-GENERATION SEQUENCING HLA TYPING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)</i>	164
NGS DIAGNOSTIC MARKETS BY REGION	165
<i>TABLE 81 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	165
NORTH AMERICA	165
<i>TABLE 82 NORTH AMERICAN NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	166
EUROPE	166
<i>TABLE 83 EUROPEAN NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	167
CHINA	168
<i>TABLE 84 CHINA NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	169
JAPAN	170
<i>TABLE 85 JAPANESE NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	170
REST OF WORLD	171
<i>TABLE 86 REST OF WORLD NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	171
CHAPTER 9 PATENTS	174

<b>TOPIC</b>	<b>PAGE NO.</b>
CLINICAL NGS PATENTS	174
<i>TABLE 87 CLINICAL NEXT-GENERATION SEQUENCING PATENTS, 2004-2014</i>	174
CLINICAL NGS PATENTS BY INDICATION	174
<i>TABLE 88 CLINICAL NEXT-GENERATION SEQUENCING PATENTS BY INDICATION, 2004-2014</i>	175
STATUS OF MYRIAD'S BRCA PATENTS	175
SEQUENOM AND ILLUMINA NIPT PATENT POOL	176
CHAPTER 10 COMPANY PROFILES	179
10X GENOMICS	179
14M GENOMICS LTD.	179
23ANDME INC.	180
<i>TABLE 89 DATA NEEDS</i>	180
ADAPTIVE BIOTECHNOLOGIES INC.	181
ADMERA HEALTH	182
AGILENT TECHNOLOGIES INC.	183
ALMAC GROUP LTD.	184
AMARANTUS BIOSCIENCE HOLDINGS INC.	185
AMBRY GENETICS	185
APPISTRY INC.	186
ARUP LABORATORIES	187
ASSUREX HEALTH	187
ASTRIDBIO TECHNOLOGIES KFT.	187
ASURAGEN INC.	188
ATHENA DIAGNOSTICS INC.	189
ATRECA INC.	189
BASE4 INNOVATION LTD.	190
BAYLOR MIRACA GENETICS LABORATORIES INC.	191
BECTON, DICKINSON AND CO.	191
BERRY GENOMICS CO. LTD.	192
BGI SHENZHEN	193
BIOARRAY SL	195
BIODESIX INC.	195
BIOINNOVATION SOLUTIONS SA	196
BIO-RAD LABORATORIES INC.	197
BIOHERANOSTICS INC.	198
BLUEPRINT GENETICS	198
BOREAL GENOMICS	199
CAREDX INC.	199
CARIS LIFE SCIENCES	200
CEGAT GMBH	200
CELLULAR RESEARCH INC.	201
CENTOGENE AG	201
CERGENTIS BV	202
CHRONIX BIOMEDICAL	202
CLARITAS GENOMICS INC.	202
CLEVELAND CLINICAL LABORATORIES	203
COFACTOR GENOMICS INC.	203

TOPIC	PAGE NO.
CORIELL LIFE SCIENCES INC.	203
CORRELAGEN DIAGNOSTICS INC.	204
COUNSYL INC.	205
COURTAGEN LIFE SCIENCES INC.	205
CYNVENIO BIOSYSTEMS INC.	206
CYPHER GENOMICS INC.	206
DANAHER CORP.	207
DIPLOID	208
DIRECTED GENOMICS LLC	208
DNA ELECTRONICS LTD.	209
DNA LINK INC.	210
DNANEXUS INC.	210
ELECTRONIC BIOSCIENCES	211
ESPERITE NV	211
EUROFINS GENOMICS	212
EXOSOME DIAGNOSTICS INC.	212
EXPRESSION ANALYSIS INC.	213
FOUNDATION MEDICINE	214
FUSION GENOMICS CORP.	215
GATC BIOTECH AG	216
GE HEALTHCARE	216
GENAPSYS INC.	217
GENDX BV	217
GENE BY GENE LTD.	218
GENEDX INC.	219
GENEPEEKS INC.	220
GENOLOGICS LIFE SCIENCES SOFTWARE	220
GENOMATIX SOFTWARE GMBH	221
GENOMEDX	221
GENOMEQUEST INC.	222
GENOMIC EXPRESSION	223
GENOMIC HEALTH INC.	223
GENOMONCOLOGY	224
GENOSPACE	224
GIGAGEN INC.	225
GOLDEN HELIX	226
GOOD START GENETICS INC.	226
HISTOGENETICS LLC	227
HTG MOLECULAR DIAGNOSTICS INC.	228
ILLUMINA INC.	228
<i>TABLE 90 NEW PLATFORMS INTRODUCED BY ILLUMINA IN 2015</i>	229
INNOVATIONS EXCHANGE PTE. LTD.	233
INTELLIMEDIX	233
INTERPACE DIAGNOSTICS LLC	234
INVITAE	234
INVIVOSCRIBE TECHNOLOGIES INC.	235
IREPERTOIRE INC.	235



<b>TOPIC</b>	<b>PAGE NO.</b>
KAILOS GENETICS	236
KELLENX INC.	236
KEW GROUP INC.	237
KNOME INC.	237
LABORATORY CORPORATION OF AMERICA INC.	238
LABORATORY FOR MOLECULAR MEDICINE	239
LASERGEN INC.	240
LEUCINE RICH BIO	240
LIFECODE INC.	241
LUMENOGIX INC.	241
MACROGEN INC.	242
MAVERIX BIOMICS INC.	242
MAYO MEDICAL LABORATORIES	242
MEDGENOME LABS PVT. LTD.	243
MEDICAL DIAGNOSTIC LABORATORIES LLC	243
MEDOMICS LLC	244
MERCK KGAA	245
MIRATI THERAPEUTICS	245
MOGENE CLINICAL DIAGNOSTICS	245
MOLECULAR HEALTH GMBH	246
MOLECULARMD CORP.	246
MRIGLOBAL RESEARCH INSTITUTE	247
MULTIPLICOM NV	247
MYRIAD GENETICS INC.	248
NABSYS INC.	249
NANTHEALTH	250
NATERA INC.	250
NEOGENOMICS INC.	251
NEW ENGLAND BIOLABS	252
NEWGENE LTD.	252
NEW ONCOLOGY AG	253
N-OF-ONE INC.	253
NOVARTIS AG	254
NUGEN TECHNOLOGIES INC.	255
OMICIA INC.	256
OMIXON BIOCOMPUTING KFT	256
ONCODNA SA	257
OXFORD GENE TECHNOLOGY	258
OXFORD NANOPORE TECHNOLOGIES LTD.	259
PACIFIC BIOSCIENCES OF CALIFORNIA INC.	260
PARABASE GENOMICS	262
PARSEQ LAB	262
PATHOGENETIX	263
PATHWAY GENOMICS CORP.	264
PERKINELMER INC.	264
PERSONAL GENOME DIAGNOSTICS INC.	266
PERSONAL GENOMICS INC.	267

<b>TOPIC</b>	<b>PAGE NO.</b>
PERSONALIS INC.	268
PICOSEQ	268
POPULATION GENETICS TECHNOLOGIES LTD.	269
<i>TABLE 91 SENSITIVITY TO DETECT DRUG RESISTANT MUTATIONS IN VIRUSES (%)</i>	270
<i>PORTABLE GENOMICS LLC</i>	271
PREMAITHA HEALTH PLC	271
PRENETICS	272
PRESSURE BIOSCIENCES INC.	272
PREVENTIONGENETICS INC.	274
QIAGEN NV	274
QUANTAPORE INC.	276
QUANTUMDX GROUP	277
QUEST DIAGNOSTICS	278
RAINDANCE TECHNOLOGIES INC.	279
REAL TIME GENOMICS INC.	280
REPROGENETICS	280
RESPONSE GENETICS INC.	281
ROCHE HOLDING AG	281
<i>TABLE 92 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING</i>	283
ROSWELL PARK CANCER INSTITUTE	284
SCIGENOM LABS	285
SELAH GENOMICS	285
SENGENICS INTERNATIONAL PTE LTD.	285
SEQUENOM INC.	286
SEVEN BRIDGES GENOMICS INC.	287
SISTEMAS GENOMICOS SL	288
SOFTGENETICS LLC	288
SOPHIA GENETICS	289
STATION X INC.	289
STRAND LIFE SCIENCES	290
STRATOS GENOMICS INC.	290
SUNDANCE DIAGNOSTICS INC.	291
SUPRATECH MICROPATH LABORATORY & RESEARCH INSTITUTE	291
SYAPSE	292
SYMBIODX	292
THERMO FISHER SCIENTIFIC INC.	293
TRANSGENOMIC INC.	294
TROVAGENE INC.	295
VELA DIAGNOSTICS	296
WAFERGEN BIOSYSTEMS INC.	297
<i>TABLE 93 WAFERGEN STRATEGIC ALLIANCES</i>	297
WARP DRIVE BIO LLC	298
YIKON GENOMICS CO. LTD.	299
ZS GENETICS INC.	299

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL CLINICAL NEXT-GENERATION SEQUENCING MARKET BY DISEASE CLASS, THROUGH 2020 (\$ MILLIONS)	8
TABLE 1 REPORT SCOPE	11
TABLE 2 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY DISEASE TYPE, THROUGH 2020 (\$ MILLIONS)	12
TABLE 3 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT-GENERATION SEQUENCING	13
TABLE 4 CLINICAL NEXT-GENERATION SEQUENCING MARKET DRIVING FORCES	15
TABLE 5 CLINICAL NEXT-GENERATION SEQUENCING APPLICATION STATUS	16
TABLE 6 KEY DIAGNOSTIC NEXT-GENERATION SEQUENCING INDUSTRY PARTICIPANTS BY SECTOR	17
TABLE 7 DNA CHEMICAL BUILDING BLOCKS	20
TABLE 8 DNA TRANSLATION AND TRANSCRIPTION	20
TABLE 9 LONG-RANGE DNA STRUCTURE	21
TABLE 10 GENETIC VARIANT TYPES	22
TABLE 11 IMPORTANT MOLECULAR DIAGNOSTIC PLATFORMS	24
TABLE 12 GENETIC TESTING EVOLUTION	25
TABLE 13 MARKET SEGMENTS FOR NEXT-GENERATION SEQUENCING DIAGNOSTICS	26
TABLE 14 DNA SEQUENCING HISTORICAL TIMELINE, 1977-2015	28
TABLE 15 SEQUENCING TECHNOLOGY DEVELOPMENT, 1990-2020	33
TABLE 16 SANGER SEQUENCING SUMMARY	35
TABLE 17 SANGER SEQUENCING IMPROVEMENTS	36
TABLE 18 NEXT-GENERATION SEQUENCING TECHNOLOGIES	37
TABLE 19 ROCHE NEXT-GENERATION SEQUENCING WORKFLOW	37
TABLE 20 ILLUMINA NEXT-GENERATION SEQUENCING WORKFLOW	38
TABLE 21 LIFE TECHNOLOGIES NEXT-GENERATION SEQUENCING WORKFLOW	39
TABLE 22 BENCHTOP SEQUENCER PLATFORMS	40
TABLE 23 NEXT-GENERATION SEQUENCING BIOINFORMATICS WORKFLOW	42
TABLE 24 SEQUENCE ANNOTATION STEPS	44
TABLE 25 FUTURE CHALLENGES FOR IMPLEMENTING CLINICAL NEXT-GENERATION SEQUENCING	46
TABLE 26 TOP 10 CLINICAL NEXT-GENERATION SEQUENCING PROJECTS	49
TABLE 27 CLINICAL NEXT-GENERATION SEQUENCING, NEAR TO MID-TERM APPLICATIONS	54
TABLE 28 CANCER APPLICATIONS	55
TABLE 29 MENDELIAN DISORDERS APPLICATIONS	57
TABLE 30 SCREENING APPLICATIONS	58
TABLE 31 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN SCREENING	60
TABLE 32 INFECTIOUS DISEASE APPLICATIONS	62
TABLE 33 COMPLEX DISORDER APPLICATIONS	64
TABLE 34 KEY SEGMENTS WITHIN THE NEXT-GENERATION SEQUENCING CLINICAL INDUSTRY	67
TABLE 35 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES SUMMARY	68
TABLE 36 NEXT-GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY	71
TABLE 37 NEXT-GENERATION SEQUENCING CLINICAL INFORMATICS COMPANY POSITIONING	73
TABLE 38 NGS CLINICAL LABORATORY TESTING SERVICES INDUSTRY	75

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 39 INDIA NGS CLINICAL SEQUENCING COMPETITIVE POSITIONING	78
TABLE 40 NGS NIPT INDUSTRY	80
TABLE 41 GLOBAL NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC MARKET SHARE BY TEST, 2014 (%)	84
TABLE 42 GERMANY NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC COMPETITIVE SITUATION	85
TABLE 43 PREIMPLANTATION DIAGNOSTICS PLATFORMS	87
TABLE 44 PREIMPLANTATION GENETIC SCREENING AND DIAGNOSIS INDUSTRY	88
TABLE 45 NGS-BASED LIQUID BIOPSY INDUSTRY	92
TABLE 46 NGS-BASED HLA TYPING INDUSTRY COMPETITORS	95
TABLE 47 IMMUNE SYSTEM PROFILING INDUSTRY	97
TABLE 48 NGS-BASED GENE FUSION DIAGNOSTICS INDUSTRY	99
TABLE 49 CLINICAL NEXT-GENERATION SEQUENCING INDUSTRY ACQUISITIONS, 2013- MARCH 2015	100
TABLE 50 CLINICAL NEXT-GENERATION SEQUENCING STRATEGIC ALLIANCES, 2013-MARCH 2015	105
TABLE 51 CLINICAL NEXT-GENERATION SEQUENCING KEY GROWTH DRIVING FORCES, THROUGH 2020	119
TABLE 52 CLINICAL NGS STAKEHOLDERS ACTIVITY	121
TABLE 53 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)	123
TABLE 54 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)	124
TABLE 55 GLOBAL NEXT-GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY SEGMENT, THROUGH 2020 (\$ MILLIONS)	126
TABLE 56 GLOBAL NEXT-GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)	129
TABLE 57 RECENT NGS-BASED COMPANION DIAGNOSTICS ACTIVITIES	132
TABLE 58 GLOBAL CANCER NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)	135
TABLE 59 MULTI-GENE NGS-BASED HEMATOLOGICAL TESTS	137
TABLE 60 GLOBAL NEXT-GENERATION SEQUENCING CARDIOVASCULAR DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)	138
TABLE 61 DILATED CARDIOMYOPATHY TEST PROVIDERS	139
TABLE 62 GLOBAL NEXT-GENERATION SEQUENCING CARDIOLOGY DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)	140
TABLE 63 GLOBAL NEXT-GENERATION SEQUENCING MENDELIAN DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)	142
TABLE 64 GLOBAL NEXT-GENERATION SEQUENCING MENDELIAN DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)	143
TABLE 65 GLOBAL NEXT-GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)	146
TABLE 66 MULTIPLE SCLEROSIS DIAGNOSTIC TECHNOLOGIES	146
TABLE 67 GLOBAL NEXT-GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)	147
TABLE 68 GLOBAL NEXT-GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)	148
TABLE 69 GLOBAL NEXT-GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)	149
TABLE 70 GLOBAL NEXT-GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)	151

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 71 GLOBAL NEXT-GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)	152
TABLE 72 GLOBAL NEXT-GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)	154
TABLE 73 GLOBAL NEXT-GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)	156
TABLE 74 GLOBAL NEXT-GENERATION SEQUENCING PREIMPLANTATION DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)	157
TABLE 75 GLOBAL NEXT-GENERATION SEQUENCING PREIMPLANTATION DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)	158
TABLE 76 GLOBAL NEXT-GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)	160
TABLE 77 GLOBAL NEXT-GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)	160
TABLE 78 NGS IN INFECTIOUS DISEASE DIAGNOSTICS	161
TABLE 79 GLOBAL NEXT-GENERATION SEQUENCING HLA TYPING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 (\$ MILLIONS)	162
TABLE 80 GLOBAL NEXT-GENERATION SEQUENCING HLA TYPING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 (\$ MILLIONS)	164
TABLE 81 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)	165
TABLE 82 NORTH AMERICAN NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	166
TABLE 83 EUROPEAN NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	167
TABLE 84 CHINA NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	169
TABLE 85 JAPANESE NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	170
TABLE 86 REST OF WORLD NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	171
TABLE 87 CLINICAL NEXT-GENERATION SEQUENCING PATENTS, 2004-2014	174
TABLE 88 CLINICAL NEXT-GENERATION SEQUENCING PATENTS BY INDICATION, 2004-2014	175
TABLE 89 DATA NEEDS	180
TABLE 90 NEW PLATFORMS INTRODUCED BY ILLUMINA IN 2015	229
TABLE 91 SENSITIVITY TO DETECT DRUG RESISTANT MUTATIONS IN VIRUSES (%)	270
TABLE 92 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING	283
TABLE 93 WAFERGEN STRATEGIC ALLIANCES	297

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL CLINICAL NEXT-GENERATION SEQUENCING MARKET BY DISEASE CLASS, 2014-2020 (\$ MILLIONS)	8
FIGURE 1 EFFECT OF NEW SEQUENCING TECHNOLOGIES ON COST TO SEQUENCE A SINGLE HUMAN GENOME, 2001-2014 [3] (\$/GENOME)	34